The staining technology used is based on Opal™ (Akoya Biosciences, Inc) staining technology, where regular antibody mediated staining with primary antibodies targeting the epitope of interest and corresponding secondary antibodies with HRP conjugates are used. Fluorophores with TSA reagent are then induced to the system. The TSA interacting with HRP results in free radicals, which form covalent bonds with nearby tyrosines. This results in high fluorophore presence on the antibodies and the nearby tissue. The antibodies are then stripped, leaving behind only the signal present on the tissue and removing any possible future antibody cross-reactivity. Through repetition of this step multiple times, multiple targets are stained with different fluorophores without cross-talk on the staining level.